NZ744468A - 2-oxindole compounds - Google Patents
2-oxindole compoundsInfo
- Publication number
- NZ744468A NZ744468A NZ744468A NZ74446817A NZ744468A NZ 744468 A NZ744468 A NZ 744468A NZ 744468 A NZ744468 A NZ 744468A NZ 74446817 A NZ74446817 A NZ 74446817A NZ 744468 A NZ744468 A NZ 744468A
- Authority
- NZ
- New Zealand
- Prior art keywords
- oxindole compounds
- compounds
- cells
- chemokines
- oxindole
- Prior art date
Links
- 150000005623 oxindoles Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000004095 oxindolyl group Chemical class N1(C(CC2=CC=CC=C12)=O)* 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 2
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662280969P | 2016-01-20 | 2016-01-20 | |
| PCT/US2017/013899 WO2017127409A1 (fr) | 2016-01-20 | 2017-01-18 | Composés de 2-oxindole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ744468A true NZ744468A (en) | 2022-07-01 |
Family
ID=59314376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ744468A NZ744468A (en) | 2016-01-20 | 2017-01-18 | 2-oxindole compounds |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20170204087A1 (fr) |
| EP (1) | EP3405455B1 (fr) |
| JP (1) | JP6898334B6 (fr) |
| KR (1) | KR20180101565A (fr) |
| CN (1) | CN108698991B (fr) |
| AR (1) | AR107398A1 (fr) |
| AU (1) | AU2017209023B2 (fr) |
| BR (1) | BR112018014666B1 (fr) |
| CA (1) | CA3011639A1 (fr) |
| ES (1) | ES2985738T3 (fr) |
| IL (1) | IL260635B (fr) |
| MA (1) | MA43799A (fr) |
| MX (1) | MX2018008895A (fr) |
| NZ (1) | NZ744468A (fr) |
| RU (1) | RU2743747C2 (fr) |
| SG (1) | SG11201806153QA (fr) |
| TW (1) | TWI729059B (fr) |
| WO (1) | WO2017127409A1 (fr) |
| ZA (1) | ZA201804966B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2743747C2 (ru) | 2016-01-20 | 2021-02-25 | Кемосентрикс, Инк. | 2-оксиндольные соединения |
| IL289037B1 (en) | 2019-07-10 | 2025-02-01 | Chemocentryx Inc | Indanes as PD-L1 inhibitors |
| WO2021076691A1 (fr) | 2019-10-16 | 2021-04-22 | Chemocentryx, Inc. | Amides hétéroaryle-biphényle pour le traitement de maladies associées à pd-l1 |
| CA3152714A1 (fr) | 2019-10-16 | 2021-04-22 | Pingchen Fan | Heteroaryl-biphenylamines pour le traitement de maladies pd-l1 |
| KR20220088448A (ko) * | 2019-10-21 | 2022-06-27 | 신에쓰 가가꾸 고교 가부시끼가이샤 | 감광성 수지 조성물, 감광성 드라이 필름 및 패턴 형성 방법 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| FR2686878B1 (fr) * | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| KR100281867B1 (ko) | 1996-01-17 | 2001-02-15 | 고바야시 유키오 | 3-(비스-치환페닐메틸렌)옥신돌유도체 |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| FR2807038B1 (fr) * | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
| AU2003230581A1 (en) | 2002-03-15 | 2003-09-29 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| DE60314175T2 (de) * | 2002-11-18 | 2008-01-24 | Chemocentryx Inc., Mountain View | Arylsulfonamide |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| ATE545416T1 (de) | 2006-10-12 | 2012-03-15 | Xenon Pharmaceuticals Inc | Verwendung von spiro-oxindol-verbindungen als therapeutika |
| FR2909668B1 (fr) * | 2006-12-12 | 2009-01-23 | Sanofi Aventis Sa | Derives de 5-alkyloxy-indolin-2-one,leur preparation et leurs applications en therapeutique |
| CA2676145A1 (fr) * | 2007-02-06 | 2008-08-14 | Novartis Ag | Derives de 1-benzenesulfonyl-1h-indole comme inhibiteurs de l'activite ccr9 |
| CN106928247A (zh) * | 2008-10-17 | 2017-07-07 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| WO2011069298A1 (fr) * | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Nouveaux dérivés de cyclopropane indolinone |
| EP2820006B1 (fr) * | 2012-02-29 | 2017-08-02 | ChemoCentryx, Inc. | Sulfonamides de pyrazol-1-yl benzène convenant comme antagonistes de ccr9 |
| US9715915B2 (en) | 2014-10-30 | 2017-07-25 | Samsung Electronics Co., Ltd. | Magneto-resistive devices including a free layer having different magnetic properties during operations |
| RU2743747C2 (ru) | 2016-01-20 | 2021-02-25 | Кемосентрикс, Инк. | 2-оксиндольные соединения |
-
2017
- 2017-01-18 RU RU2018129849A patent/RU2743747C2/ru active
- 2017-01-18 WO PCT/US2017/013899 patent/WO2017127409A1/fr active Application Filing
- 2017-01-18 US US15/408,896 patent/US20170204087A1/en not_active Abandoned
- 2017-01-18 AU AU2017209023A patent/AU2017209023B2/en active Active
- 2017-01-18 TW TW106101711A patent/TWI729059B/zh active
- 2017-01-18 MX MX2018008895A patent/MX2018008895A/es unknown
- 2017-01-18 EP EP17741838.1A patent/EP3405455B1/fr active Active
- 2017-01-18 MA MA043799A patent/MA43799A/fr unknown
- 2017-01-18 NZ NZ744468A patent/NZ744468A/en unknown
- 2017-01-18 BR BR112018014666-8A patent/BR112018014666B1/pt active IP Right Grant
- 2017-01-18 KR KR1020187023830A patent/KR20180101565A/ko not_active Application Discontinuation
- 2017-01-18 ES ES17741838T patent/ES2985738T3/es active Active
- 2017-01-18 SG SG11201806153QA patent/SG11201806153QA/en unknown
- 2017-01-18 CA CA3011639A patent/CA3011639A1/fr active Pending
- 2017-01-18 JP JP2018537816A patent/JP6898334B6/ja active Active
- 2017-01-18 CN CN201780007677.XA patent/CN108698991B/zh active Active
- 2017-01-19 AR ARP170100150A patent/AR107398A1/es unknown
-
2018
- 2018-03-07 US US15/914,900 patent/US10421748B2/en active Active
- 2018-07-17 IL IL260635A patent/IL260635B/en active IP Right Grant
- 2018-07-24 ZA ZA2018/04966A patent/ZA201804966B/en unknown
-
2019
- 2019-07-29 US US16/524,618 patent/US10759789B2/en active Active
-
2020
- 2020-07-17 US US16/932,114 patent/US11434230B2/en active Active
-
2022
- 2022-08-01 US US17/816,614 patent/US12139475B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ744468A (en) | 2-oxindole compounds | |
| Nanki et al. | Cutting edge: stromal cell-derived factor-1 is a costimulator for CD4+ T cell activation | |
| Schaerli et al. | Chemokines: control of primary and memory T-cell traffic | |
| Mosi et al. | The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor | |
| SA Capettini et al. | Role of renin-angiotensin system in inflammation, immunity and aging | |
| Choy et al. | Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis | |
| Fawaz et al. | Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: a comparative study | |
| Yuan et al. | Interleukin-17 stimulates STAT3-mediated endothelial cell activation for neutrophil recruitment | |
| Waldmann et al. | The use of antibodies against the IL-2 receptor in transplantation | |
| Juarez et al. | Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis | |
| Abebayehu et al. | Lactic acid suppresses IL-33–mediated mast cell inflammatory responses via hypoxia-inducible factor-1α–dependent miR-155 suppression | |
| Chenoweth et al. | IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells | |
| Dyugovskaya et al. | Molecular pathways of spontaneous and TNF-α–mediated neutrophil apoptosis under intermittent hypoxia | |
| Lambert et al. | Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10 | |
| DeBruyne et al. | Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor-specific immunity | |
| Xu et al. | IL-29 enhances LPS/TLR4-mediated inflammation in rheumatoid arthritis | |
| Haznedaroglu et al. | Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever | |
| Chen et al. | Pleiotropic roles of CXCR4 in wound repair and regeneration | |
| Capiralla et al. | Identification of potent small‐molecule inhibitors of STAT 3 with anti‐inflammatory properties in RAW 264.7 macrophages | |
| Tang et al. | Rheumatoid arthritis fibroblast-like synoviocytes co-cultured with PBMC increased peripheral CD4+ CXCR5+ ICOS+ T cell numbers | |
| Bulanova et al. | Mast cells express novel functional IL-15 receptor α isoforms | |
| Bakhshian Nik et al. | Interleukin 4/13 signaling in cardiac regeneration and repair | |
| Srivastava et al. | CYT387 inhibits the hyperproliferative potential of fibroblast-like synoviocytes via modulation of IL-6/JAK1/STAT3 signaling in rheumatoid arthritis | |
| Huang et al. | G-protein coupled chemoattractant receptors and cancer | |
| Margolles-Clark et al. | Suramin inhibits the CD40–CD154 costimulatory interaction: a possible mechanism for immunosuppressive effects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JAN 2024 BY COMPUTER PACKAGES INC Effective date: 20221230 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JAN 2025 BY ANAQUA SERVICES Effective date: 20231220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JAN 2026 BY ANAQUA SERVICES Effective date: 20241219 |